PROFESSIONAL EDITION

The largest community of pharma leaders

Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the departure of Dr. Sheila Gujrathi from the company’s board of directors. Dr. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio….

 

 

http://www.businesswire.com/news/home/20190609005021/en/Prime-Therapeutics-Announces-Departure-Dr.-Sheila-Gujrathi

Recent Articles